Actively Recruiting
Study of CTX-009 Combined With Gemcitabine, Cisplatin, and Durvalumab for First-Line Treatment of Unresectable or Metastatic Biliary Tract Cancers
Led by M.D. Anderson Cancer Center · Updated on 2026-09-09
50
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of CTX-009 with standard therapy consisting of Gemcitabine, Cisplatin, and Durvalumab as a first treatment for patients with unresectable or metastatic biliary tract cancers. The study aims to assess the safety and tolerability of this combination, determine the maximum tolerated dose of CTX-009, and evaluate progression-free survival over six months. Additional goals include measuring response rates, duration of response, and overall survival. Participants will receive the combination therapy intravenously on an outpatient basis. The study includes two phases a safety lead-in phase to assess tolerability and an expansion phase to further evaluate the treatment. The drugs Gemcitabine, Cisplatin, Durvalumab, and CTX-009 are all administered by IV. Treatment continues as per study protocol while monitoring safety and disease progression. Participants will be closely monitored through regular assessments including safety evaluations and adverse event tracking throughout the study, which may last about a year. Researchers will measure treatment effects using imaging criteria and clinical evaluations according to RECIST 1.1 guidelines. The study also requires participants to have adequate organ function and performance status before starting treatment and involves ongoing monitoring for side effects and disease status.
CONDITIONS
Brief Title
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Research Team
I
Ian Hu, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here